| Moden Name | Description |
| SU-DHL-2 | Derived from human diffuse large B-cell lymphoma (DLBCL), ABC subtype; BCL2 rearranged, MYC-negative; used for BCL2-targeted therapy studies. |
| SU-DHL-4 | Germinal center B-cell (GCB) subtype DLBCL; BCL6-positive, TP53 mutant, CD20-positive; responsive to rituximab and chemotherapeutics. |
| SU-DHL-6 | GCB-DLBCL line with high BCL2 expression; TP53 wild-type; used for venetoclax sensitivity testing and apoptosis pathway analysis. |
| SU-DHL-10 | Derived from GCB-DLBCL; BCL6 rearranged, CD20-positive; used to test CD20-targeted and chemotherapy combination strategies. |
| Maver-1 | Mantle cell lymphoma (MCL) with t(11;14)(q13;q32) CCND1 overexpression; resistant to BTK inhibitors; used in studies of MCL drug resistance. |
| Mino | MCL model with CCND1 overexpression; exhibits sensitivity to BTK and BCL2 inhibitors; used in combination therapy evaluation. |
| NAMALWA | Burkitt lymphoma model with MYC translocation and high CD20 expression; used for rituximab efficacy studies and lymphoma immunotherapy. |
| WSU-DLCL2 | DLBCL model expressing BCL2 and CD20; used in preclinical studies of anti-CD20 monoclonal antibodies and apoptosis modulators. |
| Z-138 | MCL line with t(11;14) translocation, CCND1 overexpression, ATM mutation; used in studies of DNA damage response inhibitors. |
| U937 | Human histiocytic lymphoma/monocytic leukemia; TP53 mutant, HLA-DR-positive; widely used to study differentiation and cytokine signaling. |
| Farage | DLBCL of GCB subtype; EBV-negative, CD20-positive; used in antibody-based immunotherapy and lymphoma resistance models. |
| Pfeiffer | GCB-DLBCL with MYC overexpression, CD20-positive; commonly used to evaluate rituximab-based combination treatments. |
| REC-1 | MCL with t(11;14) and high CCND1; BTK inhibitor-sensitive; used in studies of MCL signaling and drug resistance. |
| Toledo | GCB-DLBCL model; BCL2-high, CD20-positive, TP53 mutant; used for venetoclax and anti-CD20 therapeutic evaluations. |
| HuT78 | Cutaneous T-cell lymphoma (Sézary syndrome); CD4-positive, TP53 mutant; used for studying T-cell lymphomas and HDAC inhibitors. |
| JeKo-1 | MCL model with t(11;14), overexpressing cyclin D1; BTK inhibitor-sensitive; used to test novel MCL combination therapies. |
| CCRF-SB | Derived from B-cell acute lymphoblastic leukemia (B-ALL); used to evaluate glucocorticoid resistance and leukemic stem cell biology. |
| SU-DHL-1 | Anaplastic large cell lymphoma (ALCL) model; ALK-positive, CD30-positive; used for ALK inhibitor and immunotherapy testing. |
| OCI-LY3 | Activated B-cell-like DLBCL; MYD88 L265P mutation, NF-κB pathway activation; used in IKK and BTK pathway inhibitor studies. |
| HBL-1 | ABC-DLBCL with MYD88 L265P mutation and high BCL2 expression; standard model for BTK and IRAK4 inhibitor testing. |
| OCI-LY7 | GCB-DLBCL; TP53 wild-type, CD20-positive; used for chemotherapy sensitivity testing and BCR signaling analysis. |
| HH | Cutaneous T-cell lymphoma model; CD4+, CD30+; used for preclinical testing of HDAC inhibitors and immune checkpoint therapies. |
| H9 | T-cell lymphoma line; CD4+, CD3+; used in studies of T-cell malignancies and cytokine signaling inhibitors. |
| KARPAS-422 | GCB-DLBCL; BCL2 and EZH2 mutant, CD20-positive; used for epigenetic drug screening and anti-CD20 therapies. |
| SUPT1 | T-lymphoblastic lymphoma model; CD4+, CD8+, p53 wild-type; used in studies of retroviral infections and leukemia biology. |